The U.S. Food and Drug Administration has approved the INSTI® HIV Self Test from bioLytical Laboratories Inc., making it the first one-minute HIV self-test available to American consumers. This approval marks a substantial advancement in HIV prevention efforts, providing individuals with a private, reliable method to learn their HIV status without the barriers of traditional healthcare access.
HIV remains a serious public health challenge in the United States, with an estimated 1.2 million Americans living with the virus and approximately 13% unaware of their status. Most new HIV infections come from individuals who don't know they have the virus, with over 30,000 new infections occurring annually. Early detection significantly improves treatment outcomes and reduces transmission risk, making accessible testing crucial to public health efforts.
The INSTI® HIV Self Test delivers highly accurate results in 60 seconds or less, requiring just a single drop of blood from a fingertip. Its portable and discreet design allows people to test for HIV anywhere, anytime, addressing critical gaps in screening for those who face barriers due to stigma, cost, or location. Robert Mackie, CEO of bioLytical, emphasized that "HIV testing should be simple, fast, and accessible for everyone. By offering accurate results in just 60 seconds, we are empowering people to take control of their health, without waiting for clinic appointments or lab results."
This development supports the national public health goal of Ending the HIV Epidemic (EHE), which aims to reduce HIV infections by 90% by 2030. Expanding testing access is critical to achieving this objective, as reducing undiagnosed cases helps connect people to care sooner and prevents further transmission. Ana Subramanian, Vice President of Scientific Affairs at bioLytical, noted that "The FDA approval of the INSTI® HIV Self Test reflects both the scientific integrity of our work and our commitment to expanding access to rapid, reliable diagnostics."
The test will be available soon at major retailers and online, with updates and purchasing details available through bioLytical's website. The company will manufacture the test in its state-of-the-art facility, maintaining high quality standards through its MDSAP: ISO 13485:2016 Quality Management System. As a global leader in rapid infectious disease diagnostics, bioLytical continues to expand access to fast, accurate testing solutions that address pressing healthcare challenges. Additional information about HIV statistics and public health initiatives can be found through sources like CDC: Ending the HIV Epidemic and HIV.gov: HIV Statistics.
